Protective human antibodies to prevent Cryptosporidium illness in infants and young children
Official title: Identification of protective human monoclonal antibodies for passive immunization against Cryptosporidium
Funded at Immport Therapeutics, INC. · NIH-11315417 · Data updated 2026-11-12
A patient-friendly approach to help vulnerable kids get passive immunity through powerful antibodies to cryptosporidiosis.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Immport Therapeutics, INC. NIH-funded |
| Lab location | 1 site (Irvine, United States) |
| Project start | September 9, 2026 |
| Project end | August 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $300,000 |
| NIH project number | 1R43AI197630-01 |
| Project ID | NIH-11315417 on NIH RePORTER |
Who could benefit from this research
✓Could help
Infants and young children in LMICs, malnourished children, and at-risk elderly individuals who lack effective vaccines.
✕Less likely to help
Healthy adults with no exposure risk or individuals outside target age/patient groups may not benefit.
What this research studies
This grant aims to develop and test human monoclonal antibodies that can be given to babies and young children to protect them from cryptosporidiosis when vaccines aren’t available. Researchers will focus on selecting antibodies with strong activity and durability that could be used for passive immunization in LMICs and at-risk groups like malnourished children and the elderly. The project involves lab-based antibody discovery and evaluation, with an eye toward eventual clinical use in real patients who are at high risk of severe diarrhea and related health problems. The goal is to provide an immediate protection option that complements or substitutes for vaccination in vulnerable populations.
Why it matters
Potential benefit: If successful, this work could lead to a ready-to-use antibody-based protection against cryptosporidiosis for young children and other high-risk groups.
How similar studies have gone: Previous early-phase work has shown that monoclonal antibodies can be produced to target Cryptosporidium, with potential protective effects, but this approach requires clinical development.
Where this research is happening
-
Immport Therapeutics, INC.
Irvine, United States Active
Researchers
- Principal investigator: Campo, Joseph J. — Immport Therapeutics, INC.
- Study coordinator: Campo, Joseph J.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.